The JNK signaling pathway activator, anisomycin, has been observed to enhance JUN transcription in NIH 3T3 cells [16], whereas the JNK signaling pathway inhibitor, sp600125, suppressed JUN expression in esophageal cancer cells [17]. This evidence concerns the gene MAPK8 and esophageal cancer.